Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 23 Billion KRW | 150.67% |
| 2022 | 9.17 Billion KRW | 11.68% |
| 2021 | 8.21 Billion KRW | -27.61% |
| 2020 | 11.34 Billion KRW | -16.52% |
| 2019 | 13.59 Billion KRW | -0.31% |
| 2018 | 13.63 Billion KRW | -35.73% |
| 2017 | 21.21 Billion KRW | 15.86% |
| 2016 | 18.31 Billion KRW | 72.93% |
| 2015 | 10.59 Billion KRW | 112.94% |
| 2014 | 4.97 Billion KRW | -25.35% |
| 2013 | 6.66 Billion KRW | -48.82% |
| 2012 | 13.01 Billion KRW | 97.28% |
| 2011 | 6.59 Billion KRW | -38.21% |
| 2010 | 10.68 Billion KRW | -33.21% |
| 2009 | 15.99 Billion KRW | 160.99% |
| 2008 | 6.12 Billion KRW | 138.65% |
| 2007 | -15.85 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 26.5 Billion KRW | 15.24% |
| 2024 Q3 | 34.95 Billion KRW | 6.02% |
| 2024 Q2 | 33.65 Billion KRW | 26.95% |
| 2023 Q2 | 15.33 Billion KRW | 42.75% |
| 2023 Q1 | 10.74 Billion KRW | 17.11% |
| 2023 FY | 23 Billion KRW | 150.67% |
| 2023 Q4 | 23 Billion KRW | 1.94% |
| 2023 Q3 | 22.56 Billion KRW | 47.09% |
| 2022 Q2 | 10.41 Billion KRW | -2.31% |
| 2022 Q3 | 14.32 Billion KRW | 37.6% |
| 2022 FY | 9.17 Billion KRW | 11.68% |
| 2022 Q4 | 9.17 Billion KRW | -35.95% |
| 2022 Q1 | 10.65 Billion KRW | 29.72% |
| 2021 Q2 | 7.76 Billion KRW | -46.07% |
| 2021 Q3 | 17.53 Billion KRW | 125.89% |
| 2021 Q4 | 8.21 Billion KRW | -53.14% |
| 2021 FY | 8.21 Billion KRW | -27.61% |
| 2021 Q1 | 14.39 Billion KRW | 26.8% |
| 2020 Q4 | 11.34 Billion KRW | -6.86% |
| 2020 FY | 11.34 Billion KRW | -16.52% |
| 2020 Q3 | 12.18 Billion KRW | -3.5% |
| 2020 Q2 | 12.62 Billion KRW | -8.28% |
| 2020 Q1 | 13.76 Billion KRW | 1.27% |
| 2019 Q3 | 13.16 Billion KRW | 11.4% |
| 2019 Q1 | 12.33 Billion KRW | -9.55% |
| 2019 Q2 | 11.81 Billion KRW | -4.22% |
| 2019 Q4 | 13.59 Billion KRW | 3.29% |
| 2019 FY | 13.59 Billion KRW | -0.31% |
| 2018 Q1 | 16.65 Billion KRW | -21.5% |
| 2018 FY | 13.63 Billion KRW | -35.73% |
| 2018 Q4 | 13.63 Billion KRW | 1.28% |
| 2018 Q3 | 13.46 Billion KRW | -7.16% |
| 2018 Q2 | 14.5 Billion KRW | -12.91% |
| 2017 Q2 | 21.77 Billion KRW | 9.1% |
| 2017 FY | 21.21 Billion KRW | 15.86% |
| 2017 Q4 | 21.21 Billion KRW | -7.39% |
| 2017 Q3 | 22.91 Billion KRW | 5.21% |
| 2017 Q1 | 19.96 Billion KRW | 8.99% |
| 2016 Q1 | 11.91 Billion KRW | 12.51% |
| 2016 FY | 18.31 Billion KRW | 72.93% |
| 2016 Q3 | 15.05 Billion KRW | 16.87% |
| 2016 Q4 | 18.31 Billion KRW | 21.68% |
| 2016 Q2 | 12.87 Billion KRW | 8.08% |
| 2015 Q3 | 11.22 Billion KRW | 53.61% |
| 2015 Q2 | 7.3 Billion KRW | 7.26% |
| 2015 Q1 | 6.81 Billion KRW | 36.99% |
| 2015 FY | 10.59 Billion KRW | 112.94% |
| 2015 Q4 | 10.59 Billion KRW | -5.66% |
| 2014 FY | 4.97 Billion KRW | -25.35% |
| 2014 Q4 | 4.97 Billion KRW | 174.77% |
| 2014 Q3 | 1.81 Billion KRW | -65.46% |
| 2014 Q1 | 6.25 Billion KRW | -6.14% |
| 2014 Q2 | 5.24 Billion KRW | -16.19% |
| 2013 Q3 | 6.18 Billion KRW | 33.66% |
| 2013 FY | 6.66 Billion KRW | -48.82% |
| 2013 Q4 | 6.66 Billion KRW | 7.69% |
| 2013 Q1 | 10.97 Billion KRW | -15.69% |
| 2013 Q2 | 4.62 Billion KRW | -57.83% |
| 2012 Q4 | 13.01 Billion KRW | 0.0% |
| 2012 Q1 | 11.15 Billion KRW | 69.02% |
| 2012 FY | 13.01 Billion KRW | 97.28% |
| 2011 FY | 6.59 Billion KRW | -38.21% |
| 2011 Q4 | 6.59 Billion KRW | -25.48% |
| 2011 Q3 | 8.85 Billion KRW | 8.69% |
| 2011 Q2 | 8.14 Billion KRW | 15.29% |
| 2011 Q1 | 7.06 Billion KRW | -33.83% |
| 2010 Q4 | 10.68 Billion KRW | -1.73% |
| 2010 Q1 | 15.8 Billion KRW | -1.14% |
| 2010 Q3 | 10.86 Billion KRW | -31.29% |
| 2010 FY | 10.68 Billion KRW | -33.21% |
| 2010 Q2 | 15.81 Billion KRW | 0.07% |
| 2009 Q2 | 6.72 Billion KRW | 31.59% |
| 2009 Q4 | 15.99 Billion KRW | 20.42% |
| 2009 Q3 | 13.27 Billion KRW | 97.56% |
| 2009 Q1 | 5.1 Billion KRW | -16.63% |
| 2009 FY | 15.99 Billion KRW | 160.99% |
| 2008 Q2 | 1.37 Billion KRW | 117.3% |
| 2008 Q3 | 5.75 Billion KRW | 319.73% |
| 2008 Q1 | -7.92 Billion KRW | 50.03% |
| 2008 FY | 6.12 Billion KRW | 138.65% |
| 2008 Q4 | 6.12 Billion KRW | 6.54% |
| 2007 Q2 | -9.89 Billion KRW | 11.7% |
| 2007 Q3 | -21.57 Billion KRW | -118.12% |
| 2007 Q1 | -11.2 Billion KRW | 0.0% |
| 2007 FY | -15.85 Billion KRW | 0.0% |
| 2007 Q4 | -15.85 Billion KRW | 26.52% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -161.313% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 95.979% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 92.601% |
| HANDOK Inc. | 283.45 Billion KRW | 91.885% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -14.594% |
| Yuhan Corporation | -69.18 Billion KRW | 133.246% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 88.141% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 724.053% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 95.559% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 170.922% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 69.605% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 37.559% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 72.126% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 8.391% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -161.313% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 114.39% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 88.553% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 86.544% |
| JW Holdings Corporation | 480.68 Billion KRW | 95.215% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 86.024% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -19470.456% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 85.1% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -878.236% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 86.854% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 55.745% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -161.313% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 85.469% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 93.578% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 85.1% |
| Yuhan Corporation | -69.18 Billion KRW | 133.246% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 83.086% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 61.455% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 94.64% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 85.1% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 80.212% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -40.038% |
| CKD Bio Corp. | 143.29 Billion KRW | 83.948% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 80.183% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 195.594% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 151.418% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -878.236% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 94.56% |
| Boryung Corporation | 187.72 Billion KRW | 87.747% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 132.018% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 69.605% |
| JW Lifescience Corporation | 26.09 Billion KRW | 11.84% |